Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

17.40USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$17.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,548
52-wk High
$18.95
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $781.74
Shares Outstanding(Mil.): 44.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 14 2018

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

Nov 10 2017

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Nov 07 2017

BRIEF-Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

* Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds

Oct 18 2017

BRIEF-Vanda Pharmaceutical ‍announced results from study of Tradipitant as a treatment of chronic pruritus

* Vanda Pharmaceuticals Inc - ‍announced results from randomized phase ii clinical study of Tradipitant as a monotherapy in treatment of chronic pruritus

Sep 13 2017

Competitors

Earnings vs. Estimates